Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
A pharma industry veteran with over three decades of experience in domestic as well as international markets
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Cell sorting technology supports researchers advancing new therapies
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
